
WHAT IS CLAIMED IS:

1. A compound of structural Formula I:



I

or a pharmaceutically acceptable salt thereof, wherein

one of A and B is selected from:

1) aryl, and
2) heteroaryl,

wherein aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from R^a, and

the other of A and B is selected from:

1) aryl,
2) heteroaryl,
3) -C_{1-6}alkyl-aryl,
4) -C_{3-8}cycloalkyl-aryl,
5) -C_{2-8}cycloheteroalkyl-aryl,
6) -C_{1-6}alkyl-heteroaryl,
7) -C_{3-8}cycloalkyl-heteroaryl,
8) -C_{2-8}cycloheteroalkyl-heteroaryl,
9) -C_{1-6}alkyl-O-aryl,
10) -C_{1-6}alkyl-O-heteroaryl,
11) -C_{3-12}cycloalkyl,

12) -C_{2-12}cycloheteroalkyl,

13) -C_{1-6}alkyl-C_{3-12}cycloalkyl,

14) -C_{1-6}alkyl-C_{2-12}cycloheteroalkyl,

15) -C_{1-6}alkyl-O-C_{3-12}cycloalkyl,

16) -C_{1-6}alkyl-O-C_{2-12}cycloheteroalkyl,

17) -C_{0-6}alkyl-aryl fused to a C_{4-6}cycloalkyl or C_{4-6}cycloheteroalkyl containing 1-3 heteroatoms independently selected from O, S and $N(R^h)_2$,

18) -C_{0-6}alkyl-aryl fused to a C_{4-6}cycloalkenyl or C_{4-6}cycloheteroalkenyl containing 1-3 heteroatoms independently selected from O, S and $N(R^h)_2$,

19) -C_{0-6}alkyl-heteroaryl fused to C_{4-6}cycloalkyl or C_{4-6}cycloheteroalkyl containing 1-3 heteroatoms independently selected from O, S and $N(R^h)_2$, and

20) -C_{0-6}alkyl-heteroaryl fused to C_{4-6}cycloalkenyl or C_{4-6}cycloheteroalkenyl containing 1-3 heteroatoms independently selected from O, S and $N(R^h)_2$,

wherein alkyl, cycloalkyl, cycloheteroalkyl, cycloalkenyl, aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from R^b;

R^1 is selected from the group consisting of:

1) hydrogen,

2) -C_{1-6}alkyl,

3) -C_{3-6}alkenyl,

4) -C_{3-6}alkynyl,

5) -C_{3-10}cycloalkyl,

6) -C_{2-10}cycloheteroalkyl,

7) -C_{1-6}alkyl-O-C_{1-6}alkyl-,

8) -$(CH_2)_sC(O)R^j$,

9) -$(CH_2)_sC(O)NR^eR^j$,

10) -$(CH_2)_nNR^eC(O)R^j$,

11) -$(CH_2)_nNR^eC(O)OR^j$,

12) -$(CH_2)_nNR^eC(O)N(R^e)_2$,

13) -$(CH_2)_nNR^eC(O)NR^eR^j$,

14) -$(CH_2)_nNR^eS(O)_mR^j$,

15) -$(CH_2)_n$$NR^eS(O)mN(R^e)_2$,

16) -$(CH_2)_n$$NR^eS(O)mNR^eR^j$, and

17) -$(CH_2)_n$$NR^eR^j$,

wherein each CH_2, alkyl, alkenyl, alkynyl, cycloalkyl and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from R^c;

R^2 is selected from the group consisting of:

1) hydrogen,

2) -C_{1-6}alkyl,

3) -C_{3-6}alkenyl,

4) -C_{3-6}alkynyl,

5) -C_{3-10}cycloalkyl,

6) -C_{2-10}cycloheteroalkyl,

7) -C_{1-6}alkyl-O-C_{1-6}alkyl-,

8) -$(CH_2)_s$$C(O)R^j$,

9) -$(CH_2)_s$$C(O)NR^eR^j$,

10) -$(CH_2)_n$$NR^eC(O)R^j$,

11) -$(CH_2)_n$$NR^eC(O)OR^j$,

12) -$(CH_2)_n$$NR^eC(O)N(R^e)_2$,

13) -$(CH_2)_n$$NR^eC(O)NR^eR^j$,

14) -$(CH_2)_n$$NR^eS(O)_mR^j$,

15) -$(CH_2)_n$$NR^eS(O)mN(R^e)_2$,

16) -$(CH_2)_n$$NR^eS(O)mNR^eR^j$, and

17) -$(CH_2)_n$$NR^eR^j$,

wherein each CH_2, alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or

substituted with one to five substituents selected from R^d;

R^3 is selected from the group consisting of:

1) hydrogen,
2) -C_{1-6}alkyl,
3) -C_{2-6}alkenyl,
4) -C_{2-6}alkynyl,
5) -C_{3-10}cycloalkyl,
6) -C_{2-10}cycloheteroalkyl,
7) -C_{1-6}alkyl-O-C_{1-6}alkyl-,
8) -$(CH_2)_sC(O)R^j$,
9) -$(CH_2)_sC(O)NR^eR^j$,
10) -$(CH_2)_sNR^eC(O)R^j$,
11) -$(CH_2)_sNR^eC(O)OR^j$,
12) -$(CH_2)_sNR^eC(O)N(R^e)_2$,
13) -$(CH_2)_sNR^eC(O)NR^eR^j$,
14) -$(CH_2)_sNR^eS(O)_mR^j$,
15) -$(CH_2)_sNR^eS(O)mN(R^e)_2$,
16) -$(CH_2)_sNR^eS(O)mNR^eR^j$, and
17) -$(CH_2)_sNR^eR^j$,

wherein each CH_2, alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from R^f, and

wherein R^3 and R^4 and the carbon atoms they are connected to can from a -C_{3-5}cycloalkyl ring;

R^4 is selected from the group consisting of:

1) hydrogen,
2) -C_{1-6}alkyl,
3) -C_{2-6}alkenyl,
4) -C_{2-6}alkynyl,
5) -C_{3-10}cycloalkyl,
6) -C_{2-10}cycloheteroalkyl,
7) -C_{1-6}alkyl-O-C_{1-6}alkyl-,

8) -$(CH_2)_s$C(O)Rj,

9) -$(CH_2)_s$C(O)NReRj,

10) -$(CH_2)_s$NReC(O)Rj,

11) -$(CH_2)_s$NReC(O)ORj,

12) -$(CH_2)_s$NReC(O)N$(Re)_2$,

13) -$(CH_2)_s$NReC(O)NReRj,

14) -$(CH_2)_s$NReS$(O)_m$Rj,

15) -$(CH_2)_s$NReS(O)mN$(Re)_2$,

16) -$(CH_2)_s$NReS(O)mNReRj, and

17) -$(CH_2)_s$NReRj,

wherein each CH_2, alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from Rg;

R^5 is selected from the group consisting of:

1) hydrogen, and

2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five halogen substituents;

R^6 is selected from the group consisting of:

1) hydrogen,

2) -C_{1-6}alkyl,

3) -C_{3-6}cycloalkyl, and

4) -C_{2-6}cycloheteroalkyl,

wherein each alkyl, cycloalkyl and cycloheteroalkyl is unsubstituted or substituted with one to five halogen substituents;

R^7 is selected from the group consisting of:

1) hydrogen,

2) -C_{1-6}alkyl,

3) -C_{2-6}alkenyl, and

4) -C_{2-6}alkynyl,

wherein each alkyl, alkenyl and alkynyl is unsubstituted or substituted with one to five halogen substituents;

each R^a is independently selected from the group consisting of:

1) -CF_3,
2) -OCF_3,
3) -CHF_2,
4) -$OCHF_2$,
5) –CH_2CF_3,
6) –OCH_2CF_3,
7) –CF_2CH_3,
8) CN,
9) oxo,
10) halogen,
11) –$S(O)_2C_{1\text{-}6}$alkyl,
12) -$C_{1\text{-}6}$alkyl,
13) -$C_{2\text{-}6}$alkenyl,
14) -$C_{2\text{-}6}$alkynyl,
15) -$C_{3\text{-}6}$cycloalkyl,
16) -$C_{2\text{-}6}$cycloheteroalkyl,
17) aryl,
18) heteroaryl,
19) –$C_{1\text{-}6}$alkyl-aryl,
20) –$C_{1\text{-}6}$alkyl-heteroaryl,
21) –$C_{1\text{-}6}$alkyl-$C_{3\text{-}6}$cycloalkyl,
22) –$C_{1\text{-}6}$alkyl-$C_{2\text{-}6}$cycloheteroalkyl,
23) -$C_{2\text{-}6}$alkenyl-$C_{3\text{-}6}$cycloalkyl,
24) -$C_{2\text{-}6}$alkenyl-$C_{2\text{-}6}$cycloheteroalkyl,
25) –$C_{2\text{-}6}$alkenyl-aryl,
26) -$C_{2\text{-}6}$alkenyl-heteroaryl,

27) -C_{2-6}alkynyl-C_{3-6}cycloalkyl,

28) -C_{2-6}alkynyl-C_{2-6}cycloheteroalkyl,

29) -C_{2-6}alkynyl-aryl,

30) -C_{2-6}alkynyl-heteroaryl,

31) -OH,

32) -$(CH_2)_p$-O-C_{1-6}alkyl,

33) -$(CH_2)_p$ -O-C_{2-6}alkenyl,

34) -$(CH_2)_p$ -O-C_{2-6}alkynyl,

35) –$(CH_2)_p$ -O-C_{3-6}cycloalkyl,

36) –$(CH_2)_p$ -O-C_{2-6}heterocycloalkyl,

37) –$(CH_2)_p$ -O-aryl,

38) –$(CH_2)_p$ -O-heteroaryl,

39) -OC_{1-6}alkyl-C_{3-6}cycloalkyl,

40) -OC_{1-6}alkyl-C_{2-6}heterocycloalkyl,

41) -OC_{1-6}alkyl-aryl,

42) -OC_{1-6}alkyl-heteroaryl,

43) -$S(O)_mR^i$,

44) -C_{1-6}alkyl-$S(O)_mR^i$,

45) -$N(R^k)_2$, and

46) –NR^kR^L,

wherein each R^a is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OH, C_{1-6}alkyl, and -OC_{1-6}alkyl;

each R^b is independently selected from the group consisting of:

1) -CF_3,

2) -OCF_3,

3) -CHF_2,

4) -$OCHF_2$,

5) –CH_2CF_3,

6) –OCH_2CF_3,

7) –CF_2CH_3,

8) CN,

9) oxo,

10) halogen,

11) –S(O)$_2$C$_{1\text{-}6}$alkyl,

12) -C$_{1\text{-}6}$alkyl,

13) -C$_{2\text{-}6}$alkenyl,

14) -C$_{2\text{-}6}$alkynyl,

15) -O-C$_{1\text{-}6}$alkyl,

16) -C$_{3\text{-}6}$cycloalkyl,

17) -O-C$_{3\text{-}6}$cycloalkyl,

18) -C$_{2\text{-}6}$cycloheteroalkyl,

19) aryl,

20) heteroaryl,

21) –C$_{1\text{-}6}$alkyl-aryl,

22) –C$_{1\text{-}6}$alkyl-heteroaryl,

23) –C$_{1\text{-}6}$alkyl-C$_{3\text{-}6}$cycloalkyl,

24) –C$_{1\text{-}6}$alkyl-C$_{2\text{-}6}$cycloheteroalkyl,

25) -C$_{2\text{-}6}$alkenyl-C$_{3\text{-}6}$cycloalkyl,

26) -C$_{2\text{-}6}$alkenyl-C$_{2\text{-}6}$cycloheteroalkyl,

27) –C$_{2\text{-}6}$alkenyl-aryl,

28) -C$_{2\text{-}6}$alkenyl-heteroaryl,

29) -C$_{2\text{-}6}$alkynyl-C$_{3\text{-}6}$cycloalkyl,

30) -C$_{2\text{-}6}$alkynyl-C$_{2\text{-}6}$cycloheteroalkyl,

31) -C$_{2\text{-}6}$alkynyl-aryl,

32) -C$_{2\text{-}6}$alkynyl–heteroaryl,

33) -OH,

34) -(CH$_2$)$_q$-OC$_{1\text{-}6}$alkyl,

35) -(CH$_2$)$_q$ -OC$_{2\text{-}6}$alkenyl,

36) -(CH$_2$)$_q$ -OC$_{2\text{-}6}$alkynyl,

37) –(CH$_2$)$_q$ -OC$_{3\text{-}6}$cycloalkyl,

38) –(CH$_2$)$_q$ -OC$_{2\text{-}6}$heterocycloalkyl,

39) –$(CH_2)_q$ -O-aryl,

40) –$(CH_2)_q$ -O-heteroaryl,

41) -OC_{1-6}alkyl-C_{3-6}cycloalkyl,

42) -OC_{1-6}alkyl-C_{2-6}heterocycloalkyl,

43) -OC_{1-6}alkyl-aryl,

44) -OC_{1-6}alkyl-heteroaryl,

45) -$S(O)_mR^i$,

46) -C_{1-6}alkyl-$S(O)_mR^i$,

47) -$C(O)R^L$, and

48) –NR^kR^L,

wherein each R^b is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OCF_3, CN, CH_2CF_3, CF_2CH_3, -C_{1-6}alkyl, and -OC_{1-6}alkyl;

R^c is selected from:

1) -C_{1-6}alkyl,

2) OH,

3) halogen, and

4) -OC_{1-6}alkyl,

wherein alkyl can be unsubstituted or substituted with one to three halogens;

R^d is selected from:

1) -C_{1-6}alkyl,

2) OH,

3) halogen, and

4) -OC_{1-6}alkyl,

wherein alkyl can be unsubstituted or substituted with one to three halogens;

R^e is selected from:

1) hydrogen, and

2) C_{1-6}alkyl;

R^f is selected from:

1) -C_{1-6}alkyl,
2) OH,
3) halogen, and
4) -OC_{1-6}alkyl,

wherein alkyl can be unsubstituted or substituted with one to three halogens;

R^g is selected from:

1) -C_{1-6}alkyl,
2) OH,
3) halogen, and
4) -OC_{1-6}alkyl,

wherein alkyl can be unsubstituted or substituted with one to three halogens;

R^h is selected from:

1) hydrogen, and
2) C_{1-6}alkyl;

R^i is selected from:

1) hydrogen,
2) C_{1-6}alkyl,
3) C_{3-6}cycloalkyl,
4) aryl, and
5) heteroaryl;

R^j is selected from:

1) hydrogen,
2) C_{1-6}alkyl,
3) C3-6alkenyl,
4) C3-6alkynyl,
5) C_{3-6}cycloalkyl,
6) C_{2-5}cycloheteroalkyl,

7) aryl, and

8) heteroaryl;

R^k is selected from:

1) hydrogen, and

2) $C_{1\text{-}6}$alkyl;

R^L is selected from:

1) hydrogen,

2) $C_{1\text{-}6}$alkyl,

3) $C_{3\text{-}6}$cycloalkyl,

4) aryl, and

5) heteroaryl;

m is independently selected from 0 to 2;

n is independently selected from 2 to 6;

p is independently selected from 0 to 3;

q is independently selected from 0 to 3;

r is independently selected from 0 to 2; and

s is independently selected from 0 to 6.

2. The compound according to Claim 1 wherein A is selected from the group consisting of:

1) aryl, and

2) heteroaryl,

wherein A is unsubstituted or substituted with one to five substituents selected from R^a; or a pharmaceutically acceptable salt thereof.

3. The compound according to Claim 1 wherein A is selected from the group consisting of:

1) phenyl, and

2) pyridine,

wherein each phenyl and pyridine is unsubstituted or substituted with one to five substituents selected from R^a; or a pharmaceutically acceptable salt thereof.

4. The compound according to Claim 1 wherein A is aryl, wherein aryl is unsubstituted or substituted with one to five substituents selected from R^a; or a pharmaceutically acceptable salt thereof.

5. The compound according to Claim 1 wherein A is phenyl, wherein phenyl is unsubstituted or substituted with one to five substituents selected from R^a; or a pharmaceutically acceptable salt thereof.

~~6. The compound according to Claim 1 wherein B is independently selected from the group consisting of:~~

~~1) aryl,~~

~~2) heteroaryl,~~

~~3) -C_{1-6}alkyl-aryl,~~

~~4) -C_{3-8}cycloalkyl-aryl,~~

~~5) -C_{2-8}cycloheteroalkyl-aryl,~~

~~6) -C_{1-6}alkyl-heteroaryl,~~

~~7) -C_{3-8}cycloalkyl-heteroaryl,~~

~~8) -C_{2-8}cycloheteroalkyl-heteroaryl,~~

~~9) -C_{1-6}alkyl-O-aryl,~~

~~10) -C_{1-6}alkyl-O-heteroaryl,~~

~~11) -C_{3-12}cycloalkyl,~~

~~12) -C_{2-12}cycloheteroalkyl,~~

~~13) -C_{1-6}alkyl-C_{3-12}cycloalkyl,~~

~~14) -C_{1-6}alkyl-C_{2-12}cycloheteroalkyl,~~

~~15) -C_{1-6}alkyl-O-C_{3-12}cycloalkyl,~~

~~16) -C_{1-6}alkyl-O-C_{2-12}cycloheteroalkyl,~~

~~17) -C_{0-6}alkyl-aryl fused to C_{4-6}cycloalkyl or C_{4-6}cycloheteroalkyl containing 1-3 heteroatoms independently selected from O, S and N(R^h)$_2$,~~

~~18) -C0-6alkyl-aryl fused to C4-6cycloalkenyl or C4-6cycloheteroalkenyl containing 1-3 heteroatoms independently selected from O, S and N(Rh)2,~~

~~19) -C0-6alkyl-heteroaryl fused to C4-6cycloalkyl or C4-6cycloheteroalkyl containing 1-3 heteroatoms independently selected from O, S and N(Rh)2, and~~

~~20) -C0-6alkyl-heteroaryl fused to C4-6cycloalkenyl or C4-6cycloheteroalkenyl containing 1-3 heteroatoms independently selected from O, S and N(Rh)2,~~

~~wherein alkyl, cycloalkyl, cycloheteroalkyl, cycloalkenyl, aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from Rb; or a pharmaceutically acceptable salt thereof.~~

~~7~~6. The compound according to Claim 1 wherein B is independently selected from the group consisting of:

1) aryl,
2) heteroaryl,
3) -C1-6alkyl-aryl,
4) -C1-6alkyl-O-aryl,
5) -C1-6alkyl-O-heteroaryl,
6) -C3-12cycloalkyl,
7) -C2-12cycloheteroalkyl,
8) -C1-6alkyl-C3-12cycloalkyl,
9) -C1-6alkyl-C2-12cycloheteroalkyl,
10) -C1-6alkyl-O-C3-12cycloalkyl, and
11) -C0-6alkyl-aryl fused to C4-6cycloalkyl or C4-6cycloheteroalkyl containing 1-3 heteroatoms independently selected from O, S and N(Rh)2,

wherein alkyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from Rb; or a pharmaceutically acceptable salt thereof.

~~8~~7. The compound according to Claim 1 wherein B is independently selected from the group consisting of:

1) aryl,
2) heteroaryl, and

3) C_{3-12}cycloalkyl,

wherein cycloalkyl, aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from R^b; or a pharmaceutically acceptable salt thereof.

~~98~~98. The compound according to Claim 1 wherein B is independently selected from the group consisting of:

1) phenyl,
2) pyridine,
3) thiazole,
4) pyrimidine,
5) pyrazine,
6) pyridazine,
7) imidazole,
8) pyrazole,
9) oxazole,
10) benzofuran,
11) benzo[d]oxazole,
12) benzo[d]thiazole,
13) indazole,
14) thiazolo[5,4-b]pyridine,
15) pyrazolo[1,5-a]pyridine,
16) -$(CH_2)_2$-phenyl,
17) -CH_2-O-phenyl,
18) -CH_2-O-pyridine,
19) cyclobutane,
20) cyclohexane,
21) bicyclo[1.1.1]pentane,
22) spiro[3.3]heptane,
23) azetidine,
24) piperidine,
25) tetrahydropyran,
26) tetrahydrofuran,
27) azabicyclo[3.1.0]hexane,

28) -CH_2-cyclohexane,

29) -CH_2-tetrahydropyran,

30) -CH_2-O-cyclohexane, and

31) bicyclo[4.2.0]octatriene,

wherein B is unsubstituted or substituted with one to five substituents selected from R^b;

or a pharmaceutically acceptable salt thereof.

~~10~~9. The compound according to Claim 1 wherein B is independently selected from the group consisting of:

1) phenyl,

2) pyridine,

3) thiazole, and

4) cyclobutane,

wherein B is unsubstituted or substituted with one to five substituents selected from R^b;

or a pharmaceutically acceptable salt thereof.

~~11~~10. The compound according to Claim 1 wherein

R^1 is selected from the group consisting of:

1) hydrogen, and

2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^c;

R^2 is selected from the group consisting of:

1) hydrogen, and

2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^d;

R^3 is selected from the group consisting of:

1) hydrogen, and

2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^f;

R^4 is selected from the group consisting of:

1) hydrogen, and
2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^g;

R^5 is selected from the group consisting of:

1) hydrogen, and
2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five halogen substituents;

R^6 is selected from the group consisting of:

1) hydrogen, and
2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five halogen substituents; and

R^7 is selected from the group consisting of:

1) hydrogen, and
2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five halogen substituents;
or a pharmaceutically acceptable salt thereof.

~~12~~11. The compound according to Claim 1 wherein R^1, R^2, R^3, R^4, R^5, R^6 and R^7 are each hydrogen; or a pharmaceutically acceptable salt thereof.

~~13. The compound according to Claim 1 wherein each R^a is independently selected from the group consisting of:~~

~~1) -CF_3,~~

~~2) -OCF_3,~~

~~3) -CHF_2,~~

4) -OCH_2CF_3,

5) -CN,

6) halogen, and

7) -C_{2-6}alkynyl,

wherein each R^a is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OH, C_{1-6}alkyl, and OC_{1-6}alkyl, or a pharmaceutically acceptable salt thereof.

14. The compound according to Claim 1 wherein each R^a is independently selected from the group consisting of:

1) -CF_3,

2) -OCF_3, and

3) halogen;

or a pharmaceutically acceptable salt thereof.

15. The compound according to Claim 1 wherein each R^b is independently selected from the group consisting of:

1) -CF_3,

2) -OCF_3,

3) -CHF_2,

4) -$OCHF_2$,

5) -CH_2CF_3,

6) -$CH(CF_3)CH_3$,

7) -OCH_2CF_3,

8) -CN,

9) halogen,

10) -$S(O)_2C_{1-6}$alkyl,

11) -C_{1-6}alkyl, and

12) -C_{3-6}cycloalkyl,

wherein each R^b is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OCF_3, CN, CH_2CF_3, CF_2CH_3, -C_{1-6}alkyl, and O-C_{1-6}alkyl; or a pharmaceutically acceptable salt thereof.

~~16. The compound according to Claim 1 wherein each R^b is independently selected from the group consisting of:~~

~~(1) $-CF_3$,~~

~~(2) $-OCF_3$,~~

~~(3) $-OCH_2CF_3$, and~~

~~(4) halogen,~~

~~wherein each R^b is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OCF_3, CN, CH_2CF_3, CF_2CH_3, $-C_{1-6}$alkyl, and O-C_{1-6}alkyl; or a pharmaceutically acceptable salt thereof.~~

~~17~~12. The compound according to Claim 1 wherein

A is selected from the group consisting of:

1) aryl, and
2) heteroaryl,

wherein A is unsubstituted or substituted with one to five substituents selected from R^a;

B is independently selected from the group consisting of:

1) aryl,
2) heteroaryl,
3) -C_{1-6}alkyl-aryl,
4) -C_{1-6}alkyl-O-aryl,
5) -C_{1-6}alkyl-O-heteroaryl,
6) -C_{3-12}cycloalkyl,
7) -C_{2-12}cycloheteroalkyl,
8) -C_{1-6}alkyl-C_{3-12}cycloalkyl,
9) -C_{1-6}alkyl-C_{2-12}cycloheteroalkyl,
10) -C_{1-6}alkyl-O-C_{3-12}cycloalkyl, and
11) -C_{0-6}alkyl-aryl fused to C_{4-6}cycloalkyl or C_{4-6}cycloheteroalkyl containing 1-3 heteroatoms independently selected from O, S and $N(R^h)_2$,

wherein alkyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from R^b;

R^1 is selected from the group consisting of:

(1) hydrogen, and

(2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^c;

R^2 is selected from the group consisting of:

(1) hydrogen, and

(2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^d;

R^3 is selected from the group consisting of:

1) hydrogen, and

2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^f;

R^4 is selected from the group consisting of:

1) hydrogen, and

2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R^g;

R^6 is selected from the group consisting of:

1) hydrogen, and

2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five halogen substituents;

R^7 is selected from the group consisting of:

1) hydrogen, and

2) -C_{1-6}alkyl,

wherein each alkyl is unsubstituted or substituted with one to five halogen substituents;

each R^a is independently selected from the group consisting of:

1) -CF_3,

2) -OCF_3,

3) -CHF_2,

4) -OCH_2CF_3,

5) CN,

6) halogen, and

7) -C_{2-6}alkynyl,

wherein each R^a is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OH, C_{1-6}alkyl, and -OC_{1-6}alkyl;

each R^b is independently selected from the group consisting of:

1) -CF_3,

2) -OCF_3,

3) -CHF_2,

4) -$OCHF_2$,

5) –CH_2CF_3,

6) –$CH(CF_3)CH_3$,

7) –OCH_2CF_3,

8) CN,

9) halogen,

10) –$S(O)_2C_{1-6}$alkyl,

11) -C_{1-6}alkyl, and

12) -C_{3-6}cycloalkyl,

wherein each R^b is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OCF_3, CN, CH_2CF_3, CF_2CH_3, -C_{1-6}alkyl, and O-C_{1-6}alkyl;

or a pharmaceutically acceptable salt thereof.

~~18~~13. The compound according to Claim 1 wherein

A is aryl, wherein aryl is unsubstituted or substituted with one to five substituents selected from R^a;

B is independently selected from the group consisting of:

1) aryl,
2) heteroaryl, and
3) C_{3-12}cycloalkyl,

wherein cycloalkyl, aryl and heteroaryl are unsubstituted or substituted with one to five substituents selected from R^b;

R^1, R^2, R^3, R^4, R^5, R^6 and R^7 are hydrogen;

each R^a is independently selected from the group consisting of:

1) $-CF_3$,
2) $-OCF_3$, and
3) halogen;

each R^b is independently selected from the group consisting of:

1) $-CF_3$,
2) $-OCF_3$,
3) $–OCH_2CF_3$, and
4) halogen,

wherein each R^b is unsubstituted or substituted with one to six substituents selected from halogen, CF_3, OCF_3, CN, CH_2CF_3, CF_2CH_3, $-C_{1-6}$alkyl, and $O-C_{1-6}$alkyl;
or a pharmaceutically acceptable salt thereof.

~~19~~14. The compound according to Claim 1 selected from:

1) (S)-N-((R)-2-(3-chloro-4-fluorophenoxy)-1-(3-chloro-4-fluorophenyl)ethyl)-2-oxoimidazolidine-4-carboxamide;

2) (S)-N-((S)-2-(3-chloro-4-fluorophenoxy)-1-(3-chloro-4-fluorophenyl)ethyl)-2-oxoimidazolidine-4-carboxamide;

3) (R)-N-(bis(4-chlorophenyl)methyl)-3-methyl-2-oxoimidazolidine-4-carboxamide and (S)-N-(bis(4-chlorophenyl)methyl)-3-methyl-2-oxoimidazolidine-4-carboxamide;

4) (S)-N-((R)-(5-chloro-6-(difluoromethyl)pyridin-2-yl)(5-chloro-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

5) (S)-N-((S)-(5-chloro-6-(difluoromethyl)pyridin-2-yl)(5-chloro-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

6) (S)-N-((R)-(3-chloro-4-fluorophenyl)(5-(trifluoromethyl)-1H-pyrazol-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

7) (S)-N-((S)-(3-chloro-4-fluorophenyl)(5-(trifluoromethyl)-1H-pyrazol-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

8) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(1-(1-(trifluoromethyl)cyclopropyl)piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

9) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(1-(1-(trifluoromethyl)cyclopropyl)piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

10) (S)-N-((5-chloro-4-(trifluoromethyl)pyrimidin-2-yl)(4-chlorophenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

11) (S)-N-((R)-(5-fluoro-6-(trifluoromethyl)pyridin-2-yl)(4-(trifluoromethoxy)phenyl)-methyl)-2-oxoimidazolidine-4-carboxamide;

12) (S)-N-((S)-(5-fluoro-6-(trifluoromethyl)pyridin-2-yl)(4-(trifluoromethoxy)phenyl)-methyl)-2-oxoimidazolidine-4-carboxamide;

13) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)((trans)-5-(trifluoromethyl)tetrahydro-2H-pyran-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

14) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)((trans)-5-(trifluoromethyl)tetrahydro-2H-pyran-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

15) (S)-N-((R)-(3-chlorophenyl)(4-(trifluoromethoxy)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

16) (S)-N-((S)-(3-chlorophenyl)(4-(trifluoromethoxy)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

17) (R)-N-[bis(4-chlorophenyl)methyl]-1-methyl-2-oxoimidazolidine-4-carboxamide;

18) (S)-N-[bis(4-chlorophenyl)methyl]-1-methyl-2-oxoimidazolidine-4-carboxamide;

19) (4S)-N-{((R)-3-chloro-4-fluorophenyl)[5-fluoro-6-(2,2,2-trifluoro-ethoxy)pyridin-2-yl]methyl}-2-oxoimidazolidine-4-carboxamide;

20) (4S)-N-{((S)-3-chloro-4-fluorophenyl)[5-fluoro-6-(2,2,2-trifluoro-ethoxy)pyridin-2-yl]methyl}-2-oxoimidazolidine-4-carboxamide;

21) (4S)-N-[((R)-3-chloro-4-fluorophenyl)(6-cyanopyridin-2-yl)methyl]-2-oxoimidazolidine-4-carboxamide;

22) (4S)-N-[((S)-3-chloro-4-fluorophenyl)(6-cyanopyridin-2-yl)methyl]-2-oxoimidazolidine-4-carboxamide;

23) (4S)-N-[((R)-5-chloro-6-cyclopropylpyridin-3-yl)(3-chloro-2,4-difluoro-phenyl)methyl]-2-oxoimidazolidine-4-carboxamide;

24) (4S)-N-[((S)-5-chloro-6-cyclo-propylpyridin-3-yl)(3-chloro-2,4-difluoro-phenyl)methyl]-2-oxoimidazolidine-4-carboxamide;

25) (4S)-N-{[(R)-5-chloro-6-(trifluoromethyl)pyridin-3-yl][5-fluoro-6-(trifluoro-methyl)pyridin-2-yl]methyl}-2-oxoimidazolidine-4-carboxamide;

26) (4S)-N-{[(S)-5-chloro-6-(trifluoromethyl)pyridin-3-yl][5-fluoro-6-(trifluoro-methyl)pyridin-2-yl]methyl}-2-oxoimidazolidine-4-carboxamide;

27) (S)-N-((R)-(3-chloro-4-fluorophenyl)(cis-2,6-dimethyl-1-(2,2,2-trifluoroethyl)-piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

28) (S)-N-((S)-(3-chloro-4-fluorophenyl)(cis-2,6-dimethyl-1-(2,2,2-trifluoroethyl)-piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

29) (S)-N-((R)-(3-chloro-4-fluorophenyl)(2-(1-(trifluoromethyl)cyclopropyl)thiazol-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

30) (S)-N-((S)-(3-chloro-4-fluorophenyl)(2-(1-(trifluoromethyl)cyclopropyl)thiazol-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

31) (S)-N-((R)-(4-chlorophenyl)(4-fluoro-3-(trifluoro-methyl)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

32) (S)-N-((S)-(4-chlorophenyl)(4-fluoro-3-(trifluoro-methyl)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

33) (S)-N-((R)-(3-chloro-4-fluoro-phenyl)(4-cyano-phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

34) (S)-N-((S)-(3-chloro-4-fluoro-phenyl)(4-cyano-phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

35) (S)-2-oxo-N-((R)-(6-(trifluoromethyl)pyridin-3-yl)(2-(trifluoromethyl)thiazol-4-yl)methyl)imidazolidine-4-carboxamide;

36) (S)-2-oxo-N-((S)-(6-(trifluoromethyl)pyridin-3-yl)(2-(trifluoromethyl)thiazol-4-yl)methyl)imidazolidine-4-carboxamide;

37) (R)-N-(bis(4-chlorophenyl)methyl)-4-methyl-2,5-dioxoimidazolidine-4-carboxamide;

38) (S)-N-(bis(4-chlorophenyl)methyl)-4-methyl-2,5-dioxoimidazolidine-4-carboxamide;

39) (R)-N-(bis(4-chlorophenyl)methyl)-3-(2-hydroxyethyl)-2-oxoimidazolidine-4-carboxamide;

40) (S)-N-(bis(4-chlorophenyl)methyl)-3-(2-hydroxyethyl)-2-oxoimidazolidine-4-carboxamide;

41) (S)-N-((R)-(4-chlorophenyl)(2-(trifluoromethyl)-1H-imidazol-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

42) (S)-N-((S)-(4-chlorophenyl)(2-(trifluoromethyl)-1H-imidazol-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

43) (S)-N-((R)-1-(3-chloro-2,4-difluorophenyl)-2-((cis)-4-(trifluoromethyl)cyclohexyl)ethyl)-2-oxoimidazolidine-4-carboxamide;

44) (S)-N-((R)-1-(3-chloro-2,4-difluorophenyl)-2-((trans)-4-(trifluoromethyl)cyclohexyl)-ethyl)-2-oxoimidazolidine-4-carboxamide;

45) (S)-N-((S)-1-(3-chloro-2,4-difluorophenyl)-2-((trans)-4-(trifluoromethyl)cyclohexyl)-ethyl)-2-oxoimidazolidine-4-carboxamide;

46) (S)-N-((S)-1-(3-chloro-2,4-difluorophenyl)-2-((cis)-4-(trifluoromethyl)cyclohexyl)ethyl)-2-oxoimidazolidine-4-carboxamide;

47) (4S)-N-{(R)- (3-chloro-2,4-difluorophenyl)[6-(trifluoromethoxy)pyridin-3-yl]methyl}-2-oxoimidazolidine-4-carboxamide;

48) (4S)-N-{(S)- (3-chloro-2,4-difluorophenyl)[6-(trifluoromethoxy)pyridin-3-yl]methyl}-2-oxoimidazolidine-4-carboxamide;

49) (S)-N-((R)-1-(3-chloro-2,4-difluorophenyl)-2-(4,4-difluorocyclohexyl)ethyl)-2-oxoimidazolidine-4-carboxamide;

50) (S)-N-((S)-1-(3-chloro-2,4-difluorophenyl)-2-(4,4-difluorocyclohexyl)ethyl)-2-oxoimidazolidine-4-carboxamide;

51) (S)-N-((R)-1-(3-chloro-2,4-difluorophenyl)-2-((R)-tetrahydro-2H-pyran-3-yl)ethyl)-2-oxoimidazolidine-4-carboxamide;

52) (S)-N-((R)-1-(3-chloro-2,4-difluorophenyl)-2-((S)-tetrahydro-2H-pyran-3-yl)ethyl)-2-oxoimidazolidine-4-carboxamide;

53) (S)-N-((S)-1-(3-chloro-2,4-difluorophenyl)-2-((R)-tetrahydro-2H-pyran-3-yl)ethyl)-2-oxoimidazolidine-4-carboxamide;

54) (S)-N-((S)-1-(3-chloro-2,4-difluorophenyl)-2-((S)-tetrahydro-2H-pyran-3-yl)ethyl)-2-oxoimidazolidine-4-carboxamide;

55) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

56) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

57) ((4S)-N-{(R)-(3-chloro-4-fluorophenyl)[1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl]methyl}-2-oxoimidazolidine-4-carboxamide;

58) (4S)-N-{(S)-(3-chloro-4-fluorophenyl)[1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl]methyl}-2-oxoimidazolidine-4-carboxamide;

59) (4S)-N-{1-((R)-3-chloro-4-fluorophenyl)-2-[(4,4-difluoro-cyclohexyl)oxy]ethyl}-2-oxoimidazolidine-4-carboxamide;

60) (4S)-N-{1-((S)-3-chloro-4-fluorophenyl)-2-[(4,4-difluoro-cyclohexyl)oxy]ethyl}-2-oxoimidazolidine-4-carboxamide;

61) (4S)-N-[(R)-(3-chloro-2,4-di-fluorophenyl)(3,3-dimethylcyclobutyl)methyl]-2-oxoimidazolidine-4-carboxamide;

62) (4S)-N-[(S)-(3-chloro-2,4-di-fluorophenyl)(3,3-dimethylcyclobutyl)methyl]-2-oxoimidazolidine-4-carboxamide;

63) (S)-N-((R)-(3-chloro-4-fluorophenyl)(1-methyl-3-(tri-fluoromethyl)-1H-pyrazol-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

64) (S)-N-((S)-(3-chloro-4-fluorophenyl)(1-methyl-3-(tri-fluoromethyl)-1H-pyrazol-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

65) (S)-N-((R)-(3-chloro-4-fluorophenyl)(trans-4-(trifluoromethyl)cyclohexyl)methyl)-2-oxoimidazolidine-4-carboxamide;

66) (S)-N-((S)-(3-chloro-4-fluorophenyl)(trans-4-(trifluoromethyl)cyclohexyl)methyl)-2-oxoimidazolidine-4-carboxamide;

67) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

68) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

69) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-oxoimidazolidine-4-carboxamide;

70) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-oxoimidazolidine-4-carboxamide;

71) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(2-(2,2,2-trifluoroethoxy)thiazol-5-yl)-methyl)-2-oxoimidazolidine-4-carboxamide;

72) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(2-(2,2,2-trifluoroethoxy)thiazol-5-yl)-methyl)-2-oxoimidazolidine-4-carboxamide;

73) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(2-(difluoromethoxy)thiazol-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

74) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(2-(difluoromethoxy)thiazol-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

75) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(6,6-difluorospiro[3.3]heptan-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

76) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(6,6-difluorospiro[3.3]heptan-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

77) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(5-chloro-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

78) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(5-chloro-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

79) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-oxoimidazolidine-4-carboxamide;

80) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-oxoimidazolidine-4-carboxamide;

81) (S)-N-((R)-3-chloro-4-(trifluoromethoxy)phenyl)(5-(trifluoromethoxy)pyridin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

82) (S)-N-((S)-3-chloro-4-(trifluoromethoxy)phenyl)(5-(trifluoromethoxy)pyridin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

83) (S)-N-((R)-(5-chloro-6-cyclopropylpyridin-2-yl)(4-(trifluoromethoxy)phenyl)-methyl)-2-oxoimidazolidine-4-carboxamide;

84) (S)-N-((S)-(5-chloro-6-cyclopropylpyridin-2-yl)(4-(trifluoromethoxy)phenyl)-methyl)-2-oxoimidazolidine-4-carboxamide;

85) (S)-N-((R)-(3-chloro-4-(trifluoromethoxy)phenyl)(1-(trifluoromethyl)-1H-pyrazol-4-yl)-l3-methyl)-2-oxoimidazolidine-4-carboxamide;

86) (S)-N-((S)-(3-chloro-4-(trifluoromethoxy)phenyl)(1-(trifluoromethyl)-1H-pyrazol-4-yl)-l3-methyl)-2-oxoimidazolidine-4-carboxamide;

87) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(6-(difluoromethoxy)-5-fluoropyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

88) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(6-(difluoromethoxy)-5-fluoropyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

89) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(6-(difluoromethyl)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

90) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(6-(difluoromethyl)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

91) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(5-fluoro-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

92) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(5-fluoro-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

93) (S)-N-((R)-(5-fluoro-6-(trifluoro-methyl)pyridin-2-yl)(6-(trifluoromethoxy)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

94) (S)-N-((S)-(5-fluoro-6-(trifluoromethyl)pyridin-2-yl)(6-(trifluoromethoxy)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

95) (S)-N-((R)-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)(5-fluoro-6-(trifluoro-methyl)pyridin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

96) (S)-N-((S)-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)(5-fluoro-6-(trifluoro-methyl)-pyridin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

97) (S)-N-((R)-(3-chloro-4-(trifluoromethoxy)phenyl)(2-(trifluoromethyl)oxazol-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide

98) (S)-N-((S)-(3-chloro-4-(trifluoromethoxy)phenyl)(2-(trifluoromethyl)oxazol-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

99) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(2-(trifluoromethyl)pyrimidin-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

100) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(2-(trifluoromethyl)pyrimidin-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

101) (S)-N-((R)-3-chloro-4-(trifluoromethoxy)phenyl)(2-(trifluoromethyl)pyrimidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

102) (S)-N-((S)-3-chloro-4-(trifluoromethoxy)phenyl)(2-(trifluoromethyl)pyrimidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

103) (4S)-N-((R)-(3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridazin-3-yl)-methyl)-2-oxoimidazolidine-4-carboxamide;

104) (4S)-N-((S)-(3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridazin-3-yl)-methyl)-2-oxoimidazolidine-4-carboxamide;

105) (4S)-N-((R)-(3-chloro-2,4-difluorophenyl)(5-(2,2,2-trifluoroethoxy)pyrazin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

106) (4S)-N-((S)-(3-chloro-2,4-difluorophenyl)(5-(2,2,2-trifluoroethoxy)pyrazin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

107) (S)-N-((R)-1-(3-chloro-2,4-difluorophenyl)-3-(4-chlorophenyl)propyl)-2-oxo-imidazolidine-4-carboxamide;

108) (S)-N-((S)-1-(3-chloro-2,4-difluorophenyl)-3-(4-chlorophenyl)propyl)-2-oxo-imidazolidine-4-carboxamide;

109) (4S)-N-(1-(3-chloro-4-fluorophenyl)-2-((6-(trifluoromethyl)pyridin-3-yl)oxy)ethyl)-2-oxoimidazolidine-4-carboxamide;

110) (S)-N-((R)-1-(3-chloro-2,4-difluorophenyl)-2-cyclohexylethyl)-2-oxoimidazolidine-4-carboxamide;

111) (S)-N-((S)-1-(3-chloro-2,4-difluorophenyl)-2-cyclohexylethyl)-2-oxoimidazolidine-4-carboxamide;

112) (4S)-N-((R)-(3-chloro-2,4-difluorophenyl)(2-(difluoromethoxy)pyrimidin-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

113) (4S)-N-((S)-(3-chloro-2,4-difluorophenyl)(2-(difluoromethoxy)pyrimidin-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

114) (S)-N-((R)-(5-chloro-6-(trifluoromethyl)pyridin-2-yl)(5-chloro-6-(trifluoromethyl)-pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

115) (S)-N-((S)-(5-chloro-6-(trifluoromethyl)pyridin-2-yl)(5-chloro-6-(trifluoromethyl)-pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

116) (S)-N-((R)-(4-chloro-3-cyanophenyl)(4-(trifluoromethoxy)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

117) (S)-N-((S)-(4-chloro-3-cyanophenyl)(4-(trifluoromethoxy)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

118) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)((R)-1-(2,2,2-trifluoroethyl)piperidin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

119) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)((S)-1-(2,2,2-trifluoroethyl)piperidin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

120) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)((S)-1-(2,2,2-trifluoroethyl)piperidin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

121) (S)-N-((S)-(3-chloro-4-fluoro-phenyl)((S)-2-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

122) (S)-N-((R)-(4-chlorophenyl)(5-fluoro-4-(trifluoromethyl)pyridin-2-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

123) (S)-N-((S)-(4-chlorophenyl)(5-fluoro-4-(trifluoromethyl)pyridin-2-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

124) (S)-N-((R)-(4-chloro-3-(trifluoromethyl)-phenyl)(4-cyanophenyl)-methyl)-2-oxo-imidazolidine-4-carboxamide;

125) (S)-N-((S)-(4-chloro-3-(trifluoromethyl)-phenyl)(4-cyanophenyl)-methyl)-2-oxo-imidazolidine-4-carboxamide;

126) (S)-N-(bis(3-chloro-4-fluorophenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

127) (S)-N-((R)-(3-chloro-4-fluorophenyl)(5-chloro-6-(trifluoromethyl)pyridin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

128) (S)-N-((S)-(3-chloro-4-fluorophenyl)(5-chloro-6-(trifluoromethyl)pyridin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

129) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(6-(difluoromethyl)-5-fluoropyridin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

130) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(6-(difluoromethyl)-5-fluoropyridin-2-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

131) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(2-(difluoromethoxy)pyrimidin-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

132) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(2-(difluoromethoxy)pyrimidin-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

133) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(3-methyl-1-((S)-1,1,1-trifluoropropan-2-yl)azetidin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

134) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(3-methyl-1-((R)-1,1,1-trifluoropropan-2-yl)azetidin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

135) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(3-methyl-1-((S)-1,1,1-trifluoropropan-2-yl)azetidin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

136) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(3-methyl-1-((R)-1,1,1-trifluoropropan-2-yl)azetidin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

137) (S)-N-((R)-(3-chloro-4-fluorophenyl)(2-methylbenzo[d]thiazol-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

138) (S)-N-((S)-(3-chloro-4-fluorophenyl)(2-methylbenzo[d]thiazol-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

139) (S)-N-((R)-(3-chloro-4-fluorophenyl)(trans-2-(trifluoromethyl)cyclobutyl)methyl)-2-oxoimidazolidine-4-carboxamide;

140) (S)-N-((S)-(3-chloro-4-fluorophenyl)(trans-2-(trifluoromethyl)cyclobutyl)methyl)-2-oxoimidazolidine-4-carboxamide;

141) (4S)-N-((3-chloro-4-fluorophenyl)(3,3-dimethyl-2-(trifluoromethyl)cyclobutyl)methyl)-2-oxoimidazolidine-4-carboxamide;

142) (4S)-N-((3-chloro-4-fluorophenyl)(4-fluorobicyclo[4.2.0]octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

143) (S)-N-((R)-(3-chloro-4-fluoro-phenyl)((R)-2-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

144) (S)-N-((R)-(3-chloro-4-fluoro-phenyl)((S)-2-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

145) (S)-N-((S)-(3-chloro-4-fluoro-phenyl)((R)-2-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

146) (S)-N-((S)-(3-chloro-4-fluoro-phenyl)((S)-2-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

147) (S)-N-((R)-(3-chloro-4-fluoro-phenyl)((R)-2-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

148) (S)-N-((R)-(3-chloro-4-fluoro-phenyl)((S)-2-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

149) (S)-N-((S)-(3-chloro-4-fluoro-phenyl)((R)-2-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

150) (S)-N-((S)-(3-chloro-4-fluoro-phenyl)((S)-2-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

151) (4S)-N-((3-chloro-4-fluorophenyl)(4-chlorobicyclo[4.2.0]-octa-1(6),2,4-trien-7-yl)-methyl)-2-oxoimidazolidine-4-carboxamide;

152) (4S)-N-((3-chloro-4-fluorophenyl)(thiazolo[5,4-b]pyridin-2-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

153) (S)-N-((R)-(3-chloro-4-fluorophenyl)(5-chlorobenzofuran-2-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

154) (S)-N-((S)-(3-chloro-4-fluorophenyl)(5-chlorobenzofuran-2-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

155) (S)-N-((R)-(4-chlorophenyl)(6-(difluoromethoxy)pyridin-2-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

156) (S)-N-((S)-(4-chlorophenyl)(6-(difluoromethoxy)pyridin-2-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

157) (S)-N-((R)-(4-chlorophenyl)(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

158) (S)-N-((S)-(4-chlorophenyl)(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

159) (4S)-N-((4-chlorophenyl)(4-methyl-2-(trifluoro-methyl)thiazol-5-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

160) (4S)-N-((1(R))-(3-chloro-4-fluorophenyl)(3-(2,2,2-trifluoroethyl)-3-azabicyclo-[3.1.0]hexan-6-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

161) (4S)-N-((1(S))-(3-chloro-4-fluorophenyl)(3-(2,2,2-trifluoroethyl)-3-azabicyclo-[3.1.0]-hexan-6-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

162) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)((cis)-1-methyl-2-(trifluoro-methyl)piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

163) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)((trans)-1-methyl-2-(trifluoro-methyl)piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

164) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)((cis)-1-methyl-2-(trifluoro-methyl)-piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

165) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)((trans)-1-methyl-2-(trifluoro-methyl)-piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

166) (S)-N-((R)-(3-chloro-2,4-difluorophenyl)((cis)-5-(trifluoromethyl)-tetrahydrofuran-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

167) S)-N-((R)-(3-chloro-2,4-difluorophenyl)((trans)-5-(trifluoromethyl)-tetrahydrofuran-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

168) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)((cis)-5-(trifluoromethyl)-tetrahydrofuran-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

169) (S)-N-((S)-(3-chloro-2,4-difluorophenyl)((trans)-5-(trifluoromethyl)-tetrahydrofuran-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

170) (S)-N-((R)-(4-chlorophenyl)(pyrazolo[1,5-a]pyridin-5-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

171) (S)-N-((S)-(4-chlorophenyl)(pyrazolo[1,5-a]pyridin-5-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

172) (4S)-N-(benzo[d]thiazol-6-yl(4-chlorophenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

173) (S)-N-((R)-(4-chlorophenyl)(1H-indazol-6-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

174) (S)-N-((S)-(4-chlorophenyl)(1H-indazol-6-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

175) (S)-N-((R)-(4-chlorophenyl)(pyrazolo[1,5-a]pyridin-5-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

176) (S)-N-((S)-(4-chlorophenyl)(pyrazolo[1,5-a]pyridin-5-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

177) (S)-N-((R)-(4-chlorophenyl)(2-methylbenzo[d]oxazol-6-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

178) (S)-N-((S)-(4-chlorophenyl)(2-methylbenzo[d]oxazol-6-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

179) (S)-N-((R)-(4-chlorophenyl)(2-methylbenzo[d]thiazol-6-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

180) (S)-N-((S)-(4-chlorophenyl)(2-methylbenzo[d]thiazol-6-yl)methyl)-2-oxo-imidazolidine-4-carboxamide;

181) (S)-N-((R)-(3-chloro-4-fluorophenyl)(4-(methylsulfonyl)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

182) (S)-N-((S)-(3-chloro-4-fluorophenyl)(4-(methylsulfonyl)phenyl)methyl)-2-oxo-imidazolidine-4-carboxamide;

183) (4S)-N-[(3-chloro-4-fluorophenyl)(5-cyanopyridin-2-yl)methyl]-2-oxoimidazolidine-4-carboxamide;

184) (S)-N-((R)-benzo[d]thiazol-2-yl(3-chloro-4-fluoro-phenyl)methyl)-2-oxo-imidazolidine-4-carboxamide;

185) (S)-N-((S)-benzo[d]thiazol-2-yl(3-chloro-4-fluoro-phenyl)methyl)-2-oxo-imidazolidine-4-carboxamide;

186) (S)-N-((R)-benzo[d]oxazol-2-yl(3-chloro-4-fluoro-phenyl)methyl)-2-oxo-imidazolidine-4-carboxamide;

187) (S)-N-((S)-benzo[d]oxazol-2-yl(3-chloro-4-fluoro-phenyl)methyl)-2-oxo-imidazolidine-4-carboxamide;

188) (S)-N-((R)-(8,8-difluorobicyclo[4.2.0]octa-1(6),2,4-trien-3-yl)(4-(trifluoromethoxy)-phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

189) (S)-N-((S)-(8,8-difluorobicyclo[4.2.0]octa-1(6),2,4-trien-3-yl)(4-(trifluoromethoxy)-phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;

190) (S)-N-((R)-(4-chlorophenyl)(7,7-difluorobicyclo[4.2.0]octa-1(6),2,4-trien-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

191) (S)-N-((S)-(4-chlorophenyl)(7,7-difluorobicyclo[4.2.0]octa-1(6),2,4-trien-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

192) (4S)-N-((R)(4-chlorophenyl)((R)2,2-dimethyl-1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

193) (4S)-N-((R)(4-chlorophenyl)((S)2,2-dimethyl-1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

194) (4S)-N-((S)(4-chlorophenyl)((S)2,2-dimethyl-1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide; and

195) (4S)-N-((S)(4-chlorophenyl)((R)2,2-dimethyl-1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl)-2-oxoimidazolidine-4-carboxamide;

or a pharmaceutically acceptable salt thereof.

~~20. The compound according to Claim 1 selected from:~~

~~1) (S) N ((R) (5-fluoro-6-(trifluoromethyl)pyridin-2-yl)(4-(trifluoromethoxy)-phenyl)-methyl)-2-oxoimidazolidine-4-carboxamide;~~

~~2) (S) N ((S) (5-fluoro-6-(trifluoromethyl)pyridin-2-yl)(4-(trifluoromethoxy)-phenyl)-methyl)-2-oxoimidazolidine-4-carboxamide;~~

~~3) (S) N ((R) (3-chlorophenyl)(4-(trifluoromethoxy)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;~~

~~4) (S) N ((S) (3-chlorophenyl)(4-(trifluoromethoxy)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide;~~

~~5) (S) N ((R) (3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide ;~~

~~6) (S) N ((S) (3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide;~~

~~7) (S) N ((R) (3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-oxoimidazolidine-4-carboxamide; and~~

~~8) (S) N ((S) (3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-oxoimidazolidine-4-carboxamide;~~

~~or pharmaceutically acceptable salts thereof.~~

15. The compound according to Claim 1 which is: (S)-N-((R)-(5-fluoro-6-(trifluoromethyl)pyridin-2-yl)(4-(trifluoromethoxy)-phenyl)-methyl)-2-oxoimidazolidine-4-carboxamide; or pharmaceutically acceptable salts thereof.

16. The compound according to Claim 1 which is: (S)-N-((S)-(5-fluoro-6-(trifluoromethyl)224yridine-2-yl)(4-(trifluoromethoxy)-phenyl)-methyl)-2-oxoimidazolidine-4-carboxamide; or pharmaceutically acceptable salts thereof.

17. The compound according to Claim 1 which is: (S)-N-((R)-(3-chlorophenyl)(4-(trifluoromethoxy)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide; or pharmaceutically acceptable salts thereof.

18. The compound according to Claim 1 which is: (S)-N-((S)-(3-chlorophenyl)(4-(trifluoromethoxy)phenyl)methyl)-2-oxoimidazolidine-4-carboxamide; or pharmaceutically acceptable salts thereof.

19. The compound according to Claim 1 which is: (S)-N-((R)-(3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide; or pharmaceutically acceptable salts thereof.

20. The compound according to Claim 1 which is: (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methyl)-2-oxoimidazolidine-4-carboxamide; or pharmaceutically acceptable salts thereof.

21. The compound according to Claim 1 which is: (S)-N-(®-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-oxoimidazolidine-4-carboxamide; or pharmaceutically acceptable salts thereof.

22. The compound according to Claim 1 which is: (S)-N-((S)-(3-chloro-2,4-difluorophenyl)(trans-3-(trifluoromethyl)cyclobutyl)-methyl)-2-oxoimidazolidine-4-carboxamide; or pharmaceutically acceptable salts thereof.

~~21~~23. A pharmaceutical composition comprising a compound of any one of Claims 1-22, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

~~22~~24. ~~The use~~Use of a compound according to any one of Claims 1-22, or a pharmaceutically acceptable salt thereof, ~~for~~ in the preparation of a medicament useful for the treatment of a disorder, condition, or disease that is responsive to the inhibition of $Na_v1.8$ channel activity in a mammal in need thereof.

~~23~~25. ~~The use~~Use of a compound of any one of Claims 1-22, or a pharmaceutically acceptable salt thereof, ~~for~~ in the manufacture of a medicament for the treatment, prevention or control of a pain disorder, a cough disorder, an acute itch disorder or chronic itch disorder.

~~24~~26. The use of Claim ~~23~~ 25 wherein the disorder is a pain disorder.

~~25~~27. The use of Claim ~~24~~ 26 wherein the pain disorder is selected from: acute pain, inflammatory pain, or neuropathic pain.

~~26~~28. A compound according to any one of Claims 1-22, or a pharmaceutically acceptable salt thereof, for use in therapy.

~~27. A method of treating or preventing a disorder, condition or disease that is responsive to the inhibition of $Na_v1.8$ channel activity in a patient in need thereof comprising administration of a therapeutically effective amount of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.~~

~~28. The method of Claim 27 wherein the disorder is selected from: pain disorder, a cough disorder, an acute itch disorder or chronic itch disorder.~~

~~29. The method of Claim 28 wherein the disorder is a pain disorder.~~

~~30. The method of Claim 29 wherein the pain disorder is selected from: acute pain, inflammatory pain, or neuropathic pain.~~